View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 16, 2021updated 11 Jul 2022 2:19pm

Janssen-BMS’ drug reduces venous thromboembolism risk in Phase II TKR trial

Treatment with milvexian caused no major bleeds while one case was reported in the enoxaparin arm. 

The Janssen Pharmaceutical Companies of Johnson & Johnson and Bristol Myers Squibb (BMS ) has reported that their experimental oral drug milvexian decreased the risk of postoperative venous thromboembolism (VTE) in the Phase II AXIOMATIC-TKR clinical trial in people undergoing total knee replacement (TKR) surgery.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An inhibitor of oral factor XIa, milvexian is being jointly developed by the companies.

The randomised, parallel-group, open-label, dose-ranging, multicentre trial analysed the efficacy and safety of milvexian as against subcutaneous dose of enoxaparin in subjects undergoing TKR surgical procedure.

It enrolled 1,242 subjects, who were categorised to receive one of seven regimens of oral doses of milvexian administered twice or once-daily or a 40mg subcutaneous dose of enoxaparin once every day.

The occurrence of total VTE up to 14 days was the trial’s primary efficacy outcome.

Any bleeding, which has been described as the combination of major, clinically significant nonmajor and minimal bleeding, was the key safety outcome.

Findings showed that the trial met both the pre-specified proof-of-principle criteria of the trial.

The dose-response for efficacy with a twice-daily dose of milvexian was significant. It was also found that the 12% VTE rate with combined twice-daily doses of milvexian was substantially lower compared with the 30% rate of the prespecified benchmark.

Milvexian provided a considerably reduced risk of VTE at daily dosages of a minimum of 100mg versus enoxaparin.

Furthermore, the milvexian treatment caused no major bleeds while one case was reported in the enoxaparin arm.

Milvexian and enoxaparin respectively led to 0.8% and 1.4% rates of major plus clinically relevant nonmajor bleeds.

Bristol Myers Squibb global drug development senior vice-president and cardiovascular development head Roland Chen said: “The clear dose efficacy response without increased bleeding provides additional evidence to support our belief in the promise of milvexian.

“We look forward to results from our second Phase II trial of milvexian for secondary stroke prevention, which will add to our body of evidence for milvexian and help inform our Phase III development program.”

Another Phase II trial of milvexian for secondary stroke prevention is underway with data anticipated in the first half of next year.

Earlier this month, Janssen announced positive data from the Phase III trial of Tremfya (guselkumab) for the treatment of active psoriatic arthritis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena